Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.74 |
| ▸ | TGM2 | P21980 | 1/20 | 0.73 |
| ▸ | KRAS | P01116 | 7/20 | 0.67 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.66 |
| ▸ | IMPDH2 | P12268 | 6/20 | 0.63 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.63 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.62 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.62 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.62 |
| ▸ | HINT1 | P49773 | 1/20 | 0.61 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.61 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.61 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL574773 | 1.00 | NT5E (0.74) | NT5ETGM2KRASFUT5IMPDH2 | |
| SCHEMBL4366555 | 0.99 | NT5E (0.73) | NT5ETGM2KRASFUT5IMPDH2 | |
| SCHEMBL28597191 | 0.99 | NT5E (0.73) | NT5ETGM2KRASFUT5IMPDH2 | |
| SCHEMBL28275952 | 0.99 | NT5E (0.75) | NT5ETGM2KRASFUT5IMPDH2 | |
| SCHEMBL27819299 | 0.98 | NT5E (0.74) | NT5ETGM2KRASFUT5IMPDH2 | |
| SCHEMBL27688115 | 0.97 | NT5E (0.77) | NT5ETGM2KRASFUT5IMPDH2 | |
| SCHEMBL8501729 | 0.97 | NT5E (0.74) | NT5ETGM2KRASFUT5IMPDH2 | |
| SCHEMBL5994438 | 0.95 | NT5E (0.72) | NT5ETGM2KRASFUT5IMPDH2 | |
| SCHEMBL15747222 | 0.94 | NT5E (0.71) | NT5ETGM2KRASFUT5IMPDH2 | |
| SCHEMBL20850061 | 0.94 | NT5E (0.71) | NT5ETGM2KRASFUT5IMPDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108148840-A | For treating the aptamer therapeutics of complement-related disorders | 阿切埃米克斯股份有限公司 | 2018-06-12 | — | — | CN | disclosed |
| CN-104404046-B | For treating the aptamer therapeutics of complement related disorder | 阿切埃米克斯股份有限公司 | 2018-02-23 | — | — | CN | disclosed |
| CN-104404046-A | Aptamer therapeutics useful in the treatment of complement-related disorders | ARCHEMIX CORP | 2015-03-11 | — | — | CN | disclosed |
| CN-103352037-A | Aptamer therapeutics useful in the treatment of complement-related disorders | ARCHEMIX CORP | 2013-10-16 | — | — | CN | disclosed |
| CN-101155822-B | Aptamer therapy for the treatment of complement-related disorders | ARCHEMIX CORP | 2013-07-24 | — | — | CN | disclosed |
| CN-102657673-A | Kalii dehydrographolidi succinas freeze-dried powder compound for injection and preparation method thereof | HAINAN WEIKANG PHARM QIANSHAN | 2012-09-12 | — | — | CN | disclosed |
| CN-101116670-B | Application of compound capable of providing active methyl or of taking part in the diversion of methyl in the preparation of medicine for treating virosis | GUANGZHOU HEZHU BIOLOG TECHNOLOGY CO LTD | 2010-11-10 | — | — | CN | disclosed |
| CN-101155822-A | Aptamer therapy for the treatment of complement-related disorders | ARCHEMIX CORP (US) | 2008-04-02 | — | — | CN | disclosed |
| CN-101116670-A | Application of compound capable of providing active methyl or of taking part in the diversion of methyl in the preparation of medicine for treating virosis | GUANGZHOU HEZHU BIOLOG TECHNOL (CN) | 2008-02-06 | — | — | CN | disclosed |
| CN-1780922-A | Compositions and methods for the treatment of severe acute respiratory syndrome (SARS) | ISIS PHARMACEUTICALS INC (US) | 2006-05-31 | — | — | CN | disclosed |